GlassScriptPhysician profile
Bradley V Culling
NPI 1881950004
$23,724.85
in general payments reported to CMS, 2019-2025
21 companies · $955 in 2025
The $955 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,203 · 2020: $2,430 · 2021: $5,316 · 2022: $6,829 · 2023: $2,690 · 2024: $3,303 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,947.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21,029.29 | 2019-2025 | Octrode, Proclaim, Infinity |
| Boston Scientific Corporation | $1,230.87 | 2019-2023 | |
| Abbvie INC. | $176.55 | 2022-2024 | Ubrelvy |
| Protega Pharmaceutials INC | $154.17 | 2025 | Roxybond |
| Collegium Pharmaceutical, INC. | $151.18 | 2019-2024 | Belbuca |
| Novartis Pharmaceuticals Corporation | $146.75 | 2019-2021 | |
| Medtronic USA, INC. | $134.26 | 2020 | |
| Medtronic, INC. | $95.70 | 2021-2023 | Synchromedii |
| Teva Pharmaceuticals USA, INC. | $85.65 | 2019-2022 | |
| Pfizer INC. | $84.13 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $80.33 | 2019-2020 | |
| Amgen INC. | $68.86 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $60.66 | 2020-2021 | |
| Spr Therapeutics, INC | $58.65 | 2025 | Sprint Pns System |
| Daiichi Sankyo INC. | $41.54 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $34.23 | 2019 | |
| Scilex Pharmaceuticals INC. | $28.29 | 2019 | |
| Forte Bio-Pharma LLC | $21.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.70 | 2023 | Seglentis |
| Ibsa Pharma INC. | $14.49 | 2021 | |
| Pernix Therapeutics Holdings, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Culling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.